CD274 and colorectal carcinoma: Further studies presented the response rate was 50%, and the disease control rate was 89% in a cohort of 28 patients with MSI-high tumors.7 It remains challenging to identify CRC patients who will respond to anti-PD-1/PD-L1 treatment, which is necessary to improve the efficacy of this treatment.